SDPC's Expansion Strategy Amid 2026 Rupiah Pressures Draws Investor Interest
PT Millennium Pharmacon International Tbk (SDPC) has reaffirmed its commitment to continuing distribution expansion in Eastern Indonesia. This strategic move proceeds despite current pressures on the rupiah against the US dollar.
The pharmaceutical distribution company is focusing on strengthening infrastructure and operational efficiency to maintain business stability. Through this approach, SDPC is confident it can expand healthcare service coverage without being hindered by exchange rate fluctuations.
Impact of Rupiah Fluctuations on Distribution Business
SDPC management believes the rupiah’s depreciation does not significantly directly impact their distribution business. This is due to the company’s position in the downstream sector of the pharmaceutical supply chain.
Director of Millennium Pharmacon International, Mohamad Fazly bin Hassan, explained that currency pressure is more acutely felt by the manufacturing sector. He noted that pharmaceutical producers relying heavily on imported raw materials are most affected by the dollar’s rise.
“Our position as distributors means our business is not directly heavily impacted by rupiah or dollar fluctuations. The effects may only be felt on the manufacturing side, potentially leading to higher product prices in the market,” Fazly stated during an interview in Jakarta.
Although direct impacts are minimal, the company remains vigilant against potential operational cost increases. Rupiah depreciation often leads to higher logistics costs due to surging fuel prices and shipping rates.
To mitigate this, SDPC is tightening internal efficiencies across all operational areas. This strategy aims to preserve profit margins amid dynamic economic conditions.
Realisation of Capital Expenditure and 2026 Focus
Regarding business development plans, SDPC revealed that most major expansion agendas were successfully implemented in 2025. Consequently, investment burdens this year are lower than previous periods.
For the 2026 fiscal year, the pharmaceutical distributor allocated approximately Rp20 billion in capital expenditure (capex). This will be focused on supporting operational smoothness and maintaining existing assets.
Details of SDPC’s 2026 capex usage include:
Development and upgrading of information technology (IT) systems to enhance workflow efficiency.
Software updates to streamline stock and distribution management.
Renovation of several branch offices across Indonesia to maintain operational standards.
Fazly stated that approximately 95% of the company’s physical expansion targets were completed last year. This year’s focus is on optimising existing infrastructure to maximise its contribution to company revenue.
Currently, Millennium Pharmacon International manages 37 distribution branches spanning from western to eastern Indonesia. The company has decided not to open new branches throughout 2026.
Strategic Plan for Eastern Indonesia and IKN Penetration
Although no new branches will be opened this year, SDPC has prepared an expansion roadmap set to commence in 2027. Eastern Indonesia is the primary focus due to its substantial untapped market potential.
The company aims to open five to six new branches in strategic locations such as Kupang, Kendari, and Gorontalo. Additionally, Ambon, Jayapura, and the Nusantara Capital City (IKN) are included in the development targets.
President Director of Millennium Pharmacon International, Imam Fathorrahman, views the eastern region as a significant unexploited opportunity. Currently, pharmaceutical needs in these areas still heavily rely on local sub-distributors.
Imam outlined several reasons why Eastern Indonesia is a long-term expansion target for the company:
Consistently rising demand for pharmaceuticals and medical devices.
Limited competition from major distributors due to challenging logistics in the region.
Opportunities to increase market share through shorter, more efficient distribution chains.
The company’s desire to improve healthcare product access for remote communities.
Investing in a single branch in Eastern Indonesia is costly and requires careful planning. Imam noted that the investment for one branch office can exceed Rp5 billion.
Application of Distribution Standards and Cold Chain Facilities
In executing its expansion, SDPC prioritises quality of service alongside branch quantity. Each new branch opening is preceded by rigorous market mapping in collaboration with principals.
This ensures newly opened branches achieve strong sales and profitability. Synergy with brand owners (principals) is key to maximising local market absorption of products.
Moreover, the company closely monitors product quality throughout the distribution process until it reaches consumers. SDPC is committed to maintaining pharmaceutical quality from production to healthcare facilities.
“We ensure every MPI-distributed product retains the same quality standards as upon initial production,” Imam stated in media remarks.
As part of future strategy, SDPC is also preparing infrastructure for biotechnology products, with plans to strengthen cold chain facilities.